Skip to main navigation
Skip to content
Customer Service: 866-788-9007
PHYSICIAN LOGIN   |   CRF LOGIN   
ORDER TEST
Castle Biosciences, Inc.
  • Company
    • About Us
    • History
    • Executive Management
    • Board of Directors
    • Licenses
    • Careers
    • Contact Us
  • Products
    • Cutaneous Melanoma
    • DecisionDx-Melanoma
    • DecisionDx-CMSeq
    • Uveal Melanoma
    • DecisionDx-UM
    • DecisionDx-UMSeq
    • DecisionDx-PRAME
  • Research & Development
    • Our Approach
    • Tests in Development
    • Cutaneous Squamous Cell Carcinoma
    • Suspicious Pigmented Lesions
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
    • Financials & Filings
      • SEC Filings
    • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Investor Contact
      • Email Alerts
  • Scientific Publications
  • Resources
    • Healthcare Professionals
    • Login/Register
    • Order a Test
    • Reimbursement
    • Patients
    • Overview of our Tests
    • Frequently Asked Questions
    • Insurance Coverage
  • December 3, 2019  Castle Biosciences Announces Time Change for Presentation at the Evercore ISI Second Annual HealthCONx

RSS Feeds

RSS Feeds

RSS (Really Simple Syndication) feeds provide an easy way to keep up with news and information about our company. Most web browsers have built in RSS readers, or you can use our feeds in an RSS reader or aggregator.

Latest News Releases

Latest SEC Filings

Recent Events

Latest News
  • Castle Biosciences Announces Time Change for Presentation at the Evercore ISI Second Annual HealthCONx December 3, 2019
  • Castle Biosciences Presents Expanded Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy Recommendations November 25, 2019
  • Castle Biosciences to Present at Upcoming Investor Conferences November 20, 2019
  • Castle Biosciences Reports Third Quarter 2019 Results November 11, 2019
  • Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk October 31, 2019

Site - Investor Tools

Print Page
Print Page
RSS Feeds
RSS Feeds
Email Alerts
Email Alerts
Investor Contact
Investor Contact
Search
Search
 

Connect with Us

Company

  • About Us
  • History
  • Leadership
    • Executive Management
    • Board of Directors
  • Licenses
  • Careers
  • Contact Us

Products

  • Cutaneous Melanoma
    • DecisionDx-Melanoma
    • DecisionDx-CMSeq
  • Uveal Melanoma
    • DecisionDx-UM
    • DecisionDx-UMSeq
    • DecisionDx-PRAME

Research & Development

  • Our Approach
  • Tests in Development
  • Cutaneous Squamous Cell Carcinoma
  • Suspicious Pigmented Lesions

Latest News & Publications

  • Press Releases
  • Scientific Publications
  • Email Alerts

Resources

  • Healthcare Professionals
    • Login/Register
    • Order A Test
    • Reimbursement
  • Patients
    • Overview of our Tests
    • Frequently Asked Questions
    • Insurance Coverage
Copyright © 2019 Castle Biosciences, Inc. | All Rights Reserved
  • Privacy Policy
  • Terms of Use
  • Contact Us
7ads6x98y